Research Analysts Set Expectations for Immunome Q1 Earnings

Immunome, Inc. (NASDAQ:IMNM - Free Report) - Analysts at Lifesci Capital issued their Q1 2025 earnings estimates for shares of Immunome in a note issued to investors on Tuesday, March 11th. Lifesci Capital analyst C. Zhu expects that the company will earn ($0.61) per share for the quarter. Lifesci Capital has a "Outperform" rating and a $20.00 price objective on the stock. The consensus estimate for Immunome's current full-year earnings is ($2.21) per share. Lifesci Capital also issued estimates for Immunome's Q2 2025 earnings at ($0.61) EPS, Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.73) EPS, FY2025 earnings at ($2.62) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.81) EPS, Q3 2026 earnings at ($0.67) EPS, Q4 2026 earnings at ($0.62) EPS and FY2026 earnings at ($2.90) EPS.

A number of other research analysts have also issued reports on IMNM. Wedbush reiterated an "outperform" rating and set a $33.00 price target on shares of Immunome in a research report on Monday. Piper Sandler cut their price objective on shares of Immunome from $23.00 to $21.00 and set an "overweight" rating on the stock in a research note on Thursday, November 14th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $27.17.

Immunome Price Performance

Shares of NASDAQ IMNM traded down $0.16 during midday trading on Thursday, hitting $8.77. 453,030 shares of the company's stock were exchanged, compared to its average volume of 896,133. Immunome has a twelve month low of $8.39 and a twelve month high of $26.70. The firm has a market cap of $699.64 million, a P/E ratio of -1.08 and a beta of 1.93. The stock's 50 day moving average price is $9.98 and its 200-day moving average price is $11.80.

Remove Ads

Insider Buying and Selling at Immunome

In other news, CEO Clay B. Siegall bought 150,000 shares of the stock in a transaction that occurred on Friday, January 31st. The shares were purchased at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the acquisition, the chief executive officer now directly owns 669,636 shares in the company, valued at approximately $5,189,679. The trade was a 28.87 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Immunome

Several large investors have recently made changes to their positions in the business. JPMorgan Chase & Co. raised its holdings in shares of Immunome by 6.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company's stock worth $359,000 after purchasing an additional 1,520 shares in the last quarter. Sequoia Financial Advisors LLC increased its holdings in shares of Immunome by 11.7% in the fourth quarter. Sequoia Financial Advisors LLC now owns 19,065 shares of the company's stock valued at $202,000 after buying an additional 2,000 shares in the last quarter. Intech Investment Management LLC increased its holdings in shares of Immunome by 26.5% in the fourth quarter. Intech Investment Management LLC now owns 18,961 shares of the company's stock valued at $201,000 after buying an additional 3,974 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Immunome by 3.5% during the 4th quarter. Wellington Management Group LLP now owns 145,564 shares of the company's stock valued at $1,546,000 after acquiring an additional 4,874 shares during the last quarter. Finally, Cerity Partners LLC boosted its stake in shares of Immunome by 10.5% during the 3rd quarter. Cerity Partners LLC now owns 53,103 shares of the company's stock worth $776,000 after acquiring an additional 5,043 shares in the last quarter. Institutional investors own 44.58% of the company's stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.